RAFAEL EDUARDO CAMPO

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. ncbi Antiretroviral treatment considerations in Latino patients
    Rafael E Campo
    University of Miami School of Medicine, Miami, Florida, USA
    AIDS Patient Care STDS 19:366-74. 2005
  2. ncbi Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates
    Rafael E Campo
    Division of Infectious Diseases, University of Miami School of Medicine, Miami, Florida, USA
    J Clin Microbiol 41:3376-8. 2003
  3. ncbi Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patients
    Rafael E Campo
    University of Miami School of Medicine, Miami, Florida 33136, USA
    AIDS Patient Care STDS 21:329-38. 2007
  4. ncbi Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era
    Rafael E Campo
    Division of Infectious Diseases, University of Miami School of Medicine, Miami, Florida 33156, USA
    AIDS Patient Care STDS 19:141-9. 2005
  5. ncbi Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance
    Rafael E Campo
    Division of Infectious Diseases, University of Miami School of Medicine, 1500 NW 12th Avenue, 8th Floor West, Miami, FL 33136, USA
    AIDS Res Hum Retroviruses 19:653-6. 2003
  6. ncbi Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients
    R E Campo
    Division of Infectious Diseases, Leonard M Miller School of Medicine, University of Miami, 1120 NW14th St, Suite 863, Miami, FL 33136, USA
    Int J STD AIDS 21:166-71. 2010
  7. ncbi Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures
    Rafael E Campo
    Department of Pathology, University of Miami School of Medicine, Florida, USA
    AIDS 17:1933-9. 2003
  8. ncbi Impact of resistance to antiretroviral therapy in the minority community
    Allen E Rodriguez
    University of Miami School of Medicine, Miami, Florida, USA
    AIDS Read 14:S9-11. 2004
  9. ncbi Development of anti-retroviral resistance of HIV-1 infected individuals on therapy: is it inevitable?
    Michael A Kolber
    Division of Infectious Diseases, Department of Medicine, University of Miami School of Medicine, PO Boxc 016960, Miami, FL 33101, USA
    IUBMB Life 56:301-7. 2004
  10. ncbi Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine
    Rafael E Campo
    University of Miami School of Medicine, Miami, Florida 33136, USA
    AIDS Res Hum Retroviruses 25:269-75. 2009

Research Grants

  1. True prevalence of pre-existing reverse transcriptase inhibitor resistance in tre
    Rafael Campo; Fiscal Year: 2007

Detail Information

Publications11

  1. ncbi Antiretroviral treatment considerations in Latino patients
    Rafael E Campo
    University of Miami School of Medicine, Miami, Florida, USA
    AIDS Patient Care STDS 19:366-74. 2005
    ....
  2. ncbi Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates
    Rafael E Campo
    Division of Infectious Diseases, University of Miami School of Medicine, Miami, Florida, USA
    J Clin Microbiol 41:3376-8. 2003
    ....
  3. ncbi Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patients
    Rafael E Campo
    University of Miami School of Medicine, Miami, Florida 33136, USA
    AIDS Patient Care STDS 21:329-38. 2007
    ..ART acceptance rates among Hispanic patients were lower...
  4. ncbi Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era
    Rafael E Campo
    Division of Infectious Diseases, University of Miami School of Medicine, Miami, Florida 33156, USA
    AIDS Patient Care STDS 19:141-9. 2005
    ..Factors such as less advanced age, the presence of fewer comorbid conditions, or a less florid inflammatory response among HIV-infected individuals may account for differences in outcome of invasive PD...
  5. ncbi Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance
    Rafael E Campo
    Division of Infectious Diseases, University of Miami School of Medicine, 1500 NW 12th Avenue, 8th Floor West, Miami, FL 33136, USA
    AIDS Res Hum Retroviruses 19:653-6. 2003
    ..We hypothesize that this finding may be due to nonspecific selective pressure (i.e., to nucleoside reverse transcriptase inhibitors) selecting out PI- and, to a lesser extent, NNRTI-resistant viral variants...
  6. ncbi Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients
    R E Campo
    Division of Infectious Diseases, Leonard M Miller School of Medicine, University of Miami, 1120 NW14th St, Suite 863, Miami, FL 33136, USA
    Int J STD AIDS 21:166-71. 2010
    ..Switching from a PI- to an efavirenz-based regimen was generally safe and well tolerated...
  7. ncbi Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures
    Rafael E Campo
    Department of Pathology, University of Miami School of Medicine, Florida, USA
    AIDS 17:1933-9. 2003
    ..CONCLUSIONS: These results suggest that IDV-RTV-based regimens may be able to overcome IDV resistance. This underscores the importance of drug adherence, potency, and exposure in determining virologic responses to antiretroviral therapy...
  8. ncbi Impact of resistance to antiretroviral therapy in the minority community
    Allen E Rodriguez
    University of Miami School of Medicine, Miami, Florida, USA
    AIDS Read 14:S9-11. 2004
    ....
  9. ncbi Development of anti-retroviral resistance of HIV-1 infected individuals on therapy: is it inevitable?
    Michael A Kolber
    Division of Infectious Diseases, Department of Medicine, University of Miami School of Medicine, PO Boxc 016960, Miami, FL 33101, USA
    IUBMB Life 56:301-7. 2004
    ..Finally, we touch on the therapeutic strategy that diminished viral replication capacity of mutational species can maintain host immunity...
  10. ncbi Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine
    Rafael E Campo
    University of Miami School of Medicine, Miami, Florida 33136, USA
    AIDS Res Hum Retroviruses 25:269-75. 2009
    ..The data also suggest that measuring lopinavir concentrations is not useful in predicting virologic response in these patients...
  11. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006
    ..Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere...

Research Grants2

  1. True prevalence of pre-existing reverse transcriptase inhibitor resistance in tre
    Rafael Campo; Fiscal Year: 2007
    ..Most importantly, unrecognized resistance might impair the efficacy of antiretroviral therapy, and its timely identification could lead to better treatment outcomes. ..